Diphtheria and Tetanus Toxoids and Acellular Pertussis Articles
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
GSK's vaccine DTaP-IPV performs well at Ph III
14 May 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
US vaccine shortage addressed
24 June 2002
GSK drops late-stage diabetes drug
23 October 2001
Update - FDA panel rejects pentavalent Infanrix
15 March 2001
FDA Oks new Tripedia DTaP vaccine
12 March 2001
US panel rejects GSK pentavalent vaccine
9 March 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Strong earnings growth for Glaxo Wellcome and SmithKline Beecham
1 November 2000
Hexavalent pediatric vaccines licensed in EU
26 October 2000
CPMP backs new pediatric vaccines from SB
5 July 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
SB seeks Infanrix HepB-IPV approval in the USA
19 July 1999
SB's Infanrix cleared for pre-school booster
6 May 1999
Medeva Files For European Approval Of Hepagene
27 October 1998
Certiva DTaP Vaccine Launched In USA
16 October 1998
NAV's Certiva Vaccine Approved In USA
6 August 1998
Currency And Flu Factors Hold Back SB Results
22 July 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Euro Union CPMP September Meeting
8 October 1997
First Approval For SB's Infanrix Hep B
4 August 1997
Strong Sterling Impacts SmithKline Beecham
23 July 1997
FDA Panel Fails To Back PMC's TriHIBit Vaccine
12 June 1997
SB's Infanrix Licensed In USA
10 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
First Approval Of SB's Infanrix-DTPa+Hib
28 October 1996
SmithKline Beecham 3rd Qtr Earnings Leap 20%
28 October 1996
First Acellular DTP Vaccine Licensed For Infants In USA
12 August 1996
FDA Recommend Approval Of SKB's Infanrix
22 July 1996
SB's Infanrix gets new marketing clearance
22 January 1996
SmithKline Beecham: Infranrix launch
11 September 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
Indication Extension For SB's Infanrix
27 March 1995
SmithKline Vaccine Results
17 October 1994
Showing 1-51 of 51 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
